The utility of FDG-PET for managing patients with malignant lymphoma: Analysis of data from a single cancer center

Internal Medicine

Volumn 48, Issue 17, 2009, Pages 1509-1513

  Imataki, Osamu ^a   Tamai, Yotaro ^a   Yokoe, Koiku ^a   Furukawa, Takayoshi ^a   Kawakami, Kimihiro ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Clinical stage; Fluorodeoxyglucose positron emission tomography (FDG PET); Malignant lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; B CELL LYMPHOMA; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FOLLICULAR LYMPHOMA; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LYMPHOMA; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; T CELL LYMPHOMA;

DISEASE MANAGEMENT; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349495695     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1856     Document Type: Article

References (19)

1. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 16: 337-345, 2002.
2. Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237: 1038-1045, 2005.
3. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin's lymphoma. Blood 107: 52-59, 2006.
4. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23: 4652-4661, 2005.
5. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19: 414-419, 2001.
6. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2: 157-164, 2001.
7. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101: 3875-3876, 2003.
8. 18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19: 1154-1161, 1978.
9. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30 Suppl 1 : S117-127, 2003.
10. 18FFDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 26: 689-694, 2005.
11. Cheson BD, Pfistner B, Juweid ME, et al; The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007.
12. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 28: 288-292, 1987.
13. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203: 795-800, 1997.
14. Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25: 721-728, 1998.
15. Schiepers C. PET for staging of Hodgkin's disease and non- Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30: S82-88, 2003.
16. Spaepen K. Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 30: S97-105, 2003.
17. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F] FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30: 682-688, 2003.
18. Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in restaging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31: 325-329, 2004.
19. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46: 958-963, 2005.